Is Tetraphase Pharmaceuticals A Buyout Candidate? Brean Capital Thinks So

Loading...
Loading...
In a report published Friday, Brean Capital analyst Jonathan Aschoff said that that
Tetraphase Pharmaceuticals IncTTPH
is a "prime takeout candidate" as the company continues to target NDA submission for eravacycline for both indications (cUTI and cIAI) by the end of 2015. "MAA would be filed 3-6 months after that if Tetraphase has not found an ex-US partner, but we believe positive data from both trials would likely attract an ex-US partner for eravacycline," Aschoff wrote. "In December 2014 Tetraphase reported positive topline data from the Phase 3 IGNITE 1 trial for cIAI, with additional IGNITE 1 data to be presented at upcoming meetings in 2015." Aschoff added that the pivotal portion of IGNITE 2 for cUTI is now dosing pateints at the e IV 1.5mg/kg to oral 200mg dose of eravacycline, with top-line data readout in mid-2015. The analyst added that additional non-inferiority data from the lead-in portion of IGNITE 2 will be presented at ECCMID in April 2015. The analyst further stated that TP-6070, Tetraphase's second-generation candidate, was selected to be evaluated in IND-enabling toxicology studies given its preclinical potency against MDR Gram-negative pathogen. Shares remain Buy rated with a $50 price target.
Posted In: Analyst ColorAnalyst RatingsBrean CapitalcIAIECCMIDeravacyclineJonathan Aschoff
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...